NSI-189 is an experimental drug being studied by Neuralstem, Inc. Research into NSI-189 has been funded by the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH) for the treatment of major depressive disorder.
NSI-189 successfully completed a phase 1 clinical trial in 2011 where it was administered to 41 healthy volunteers. A phase 1b clinical trial for treating major depressive disorder in 24 patients started in 2012 and completed in July 2014. The study suggests that there were improvements in the patients' condition when the doses were 40/80 mg per day, but no significant improvements were seen for a higher dosage of 120 mg/day. Neuralstem intends to pursue further clinical trials for a variety of neurological conditions, including major depressive disorder, traumatic brain injury, Alzheimer's disease, post-traumatic stress disorder, stroke, and natural cognitive and memory decline in aging.
Certificate of Analysis-NSI-189 1270138-40-3 B15JP0412